Freeline Therapeutics Statistics Share Statistics Freeline Therapeutics has 4.36M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 4.36M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 26.8M Failed to Deliver (FTD) Shares 14 FTD / Avg. Volume 0.05%
Short Selling Information The latest short interest is 10.36K, so 0.24% of the outstanding
shares have been sold short.
Short Interest 10.36K Short % of Shares Out 0.24% Short % of Float 0.25% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.32 and the forward
PE ratio is null.
Freeline Therapeutics's PEG ratio is
0.01.
PE Ratio -0.32 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.54 P/FCF Ratio -0.33 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Freeline Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.18,
with a Debt / Equity ratio of 0.11.
Current Ratio 2.18 Quick Ratio 1.61 Debt / Equity 0.11 Debt / EBITDA -0.06 Debt / FCF -0.07 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-585.34K Employee Count 152 Asset Turnover 0 Inventory Turnover 0.1
Taxes Income Tax 368K Effective Tax Rate -0.42%
Stock Price Statistics The stock price has increased by 0.15% in the
last 52 weeks. The beta is 0.66, so Freeline Therapeutics's
price volatility has been higher than the market average.
Beta 0.66 52-Week Price Change 0.15% 50-Day Moving Average 6.42 200-Day Moving Average 4.69 Relative Strength Index (RSI) 61.01 Average Volume (20 Days) 28,144
Income Statement
Revenue n/a Gross Profit -1.74M Operating Income -98.45M Net Income -88.97M EBITDA -97.17M EBIT -98.92M Earnings Per Share (EPS) -22.52
Full Income Statement Balance Sheet The company has 47.28M in cash and 5.92M in
debt, giving a net cash position of 41.35M.
Cash & Cash Equivalents 47.28M Total Debt 5.92M Net Cash 41.35M Retained Earnings -445.35M Total Assets 49.22M Working Capital 16.52M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -78.22M
and capital expenditures -7.01M, giving a free cash flow of -85.24M.
Operating Cash Flow -78.22M Capital Expenditures -7.01M Free Cash Flow -85.24M FCF Per Share -21.57
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields FRLN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for FRLN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 12, 2023. It was a
backward
split with a ratio of 1:15.
Last Split Date May 12, 2023 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -16.92 Piotroski F-Score 2
